0A50 Stock Overview
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$1.80 |
| 52 Week Low | US$1.00 |
| Beta | -0.68 |
| 1 Month Change | 2.39% |
| 3 Month Change | 6.64% |
| 1 Year Change | -7.36% |
| 3 Year Change | -83.23% |
| 5 Year Change | n/a |
| Change since IPO | -88.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A50 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 10.3% | 2.8% | 2.0% |
| 1Y | -7.4% | -8.5% | 4.5% |
Return vs Industry: 0A50 exceeded the UK Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 0A50 underperformed the UK Market which returned 4.5% over the past year.
Price Volatility
| 0A50 volatility | |
|---|---|
| 0A50 Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A50 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A50's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 155 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
| 0A50 fundamental statistics | |
|---|---|
| Market cap | US$39.39m |
| Earnings (TTM) | -US$35.33m |
| Revenue (TTM) | US$6.81m |
5.8x
P/S Ratio-1.1x
P/E RatioIs 0A50 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A50 income statement (TTM) | |
|---|---|
| Revenue | US$6.81m |
| Cost of Revenue | US$4.18m |
| Gross Profit | US$2.63m |
| Other Expenses | US$37.96m |
| Earnings | -US$35.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 38.57% |
| Net Profit Margin | -518.68% |
| Debt/Equity Ratio | 0% |
How did 0A50 perform over the long term?
See historical performance and comparison